The most widely accepted definition of HER2 amplification is the HER2/CEP17 ratio ≥ 2.0 by fluorescence in situ hybridisation (FISH) testing, which is used in breast cancer as well as in most clinical trials. Here, ERBB2 is linked to breast carcinoma.